Cara Therapeutics, Inc. (CARA): Price and Financial Metrics

Cara Therapeutics, Inc. (CARA): $0.67

0.02 (-2.43%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

D

Add CARA to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#225 of 362

in industry

CARA Price/Volume Stats

Current price $0.67 52-week high $4.67
Prev. close $0.69 52-week low $0.50
Day low $0.65 Volume 232,217
Day high $0.70 Avg. volume 661,927
50-day MA $0.81 Dividend yield N/A
200-day MA $1.43 Market Cap 36.79M

CARA Stock Price Chart Interactive Chart >


Cara Therapeutics, Inc. (CARA) Company Bio


Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. The company was founded in 2004 and is based in Shelton, Connecticut.


CARA Latest News Stream


Event/Time News Detail
Loading, please wait...

CARA Latest Social Stream


Loading social stream, please wait...

View Full CARA Social Stream

Latest CARA News From Around the Web

Below are the latest news stories about CARA THERAPEUTICS INC that investors may wish to consider to help them evaluate CARA as an investment opportunity.

CARA's Late-Stage Skin Disease Study Fails, Stock Plummets 49%

CARA discontinues the clinical program of oral difelikefalin for pruritus associated with atopic dermatitis following the failure of dose-finding Part A of the late-stage study. Stock plunges 49%.

Yahoo | December 19, 2023

Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis

– Oral difelikefalin as adjunct to topical corticosteroids (TCS) did not demonstrate meaningful clinical benefit compared to TCS alone; As a result, Cara will discontinue its clinical program in pruritus associated with atopic dermatitis – – Late-stage oral difelikefalin clinical programs for pruritus associated with notalgia paresthetica and advanced chronic kidney disease continue to enroll on track with key data readouts expected in 2H24 – – Cara expects to end 2023 with approximately $100 mi

Yahoo | December 18, 2023

Cara Therapeutics, Inc. (NASDAQ:CARA) Q3 2023 Earnings Call Transcript

Cara Therapeutics, Inc. (NASDAQ:CARA) Q3 2023 Earnings Call Transcript November 13, 2023 Cara Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.52 EPS, expectations were $-0.5. Operator: Good afternoon. My name is Latif and I will be your conference facilitator. I would like to welcome everyone to the Cara Therapeutics Third Quarter Financial Results […]

Yahoo | November 14, 2023

Q3 2023 Cara Therapeutics Inc Earnings Call

Q3 2023 Cara Therapeutics Inc Earnings Call

Yahoo | November 14, 2023

Cara (CARA) Reports Q3 Earnings: What Key Metrics Have to Say

The headline numbers for Cara (CARA) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Yahoo | November 13, 2023

Read More 'CARA' Stories Here

CARA Price Returns

1-mo -25.79%
3-mo 18.58%
6-mo -48.06%
1-year -83.54%
3-year -97.56%
5-year -96.31%
YTD -9.83%
2023 -93.08%
2022 -11.82%
2021 -19.50%
2020 -6.08%
2019 23.92%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!